Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine

Current Opinion in Immunology

Volumn 35, Issue , 2015, Pages 131-136

  Zhou, Yan ^a   Sullivan, Nancy J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; EBOLA VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; TUMOR NECROSIS FACTOR; CYTOKINE; MVA VACCINE; VIRUS VACCINE;

ANTIBODY TITER; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CROSS REACTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; GENETIC IMMUNIZATION; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL MEMORY; MORTALITY; NONHUMAN; PASSIVE TRANSPORT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SEROPREVALENCE; SURVIVAL RATE; T CELL DEPLETION; VIRAL CLEARANCE; VIRUS REPLICATION; ADENOVIRIDAE; ANIMAL; CLINICAL TRIAL (TOPIC); GENE VECTOR; GENETICS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; MACACA; METABOLISM;

ADENOVIRIDAE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; CYTOKINES; EBOLA VACCINES; EBOLAVIRUS; GENETIC VECTORS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNOLOGIC MEMORY; MACACA; VIRAL VACCINES;

EID: 84939182741     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2015.06.006     Document Type: Review

References (34)

1. Misasi J., Sullivan N.J. Camouflage and misdirection: the full-on assault of ebola virus disease. Cell 2014, 159:477-486.
2. Xu L., Sanchez A., Yang Z., Zaki S.R., Nabel E.G., Nichol S.T., Nabel G.J. Immunization for Ebola virus infection. Nat Med 1998, 4:37-42.
3. Vanderzanden L., Bray M., Fuller D., Roberts T., Custer D., Spik K., Jahrling P., Huggins J., Schmaljohn A., Schmaljohn C. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 1998, 246:134-144.
4. Gupta M., Greer P., Mahanty S., Shieh W.J., Zaki S.R., Ahmed R., Rollin P.E. CD8-mediated protection against Ebola virus infection is perforin dependent. J Immunol 2005, 174:4198-4202.
5. Wong G., Richardson J.S., Pillet S., Patel A., Qiu X., Alimonti J., Hogan J., Zhang Y., Takada A., Feldmann H., et al. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med 2012, 4. 158ra146.
6. Choi J.H., Schafer S.C., Zhang L., Juelich T., Freiberg A.N., Croyle M.A. Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine. Mol Pharm 2013, 10:3342-3355.
7. Letvin N.L., Montefiori D.C., Yasutomi Y., Perry H.C., Davies M.E., Lekutis C., Alroy M., Freed D.C., Lord C.I., Handt L.K., et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci U S A 1997, 94:9378-9383.
8. Sullivan N.J., Sanchez A., Rollin P.E., Yang Z.Y., Nabel G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000, 408:605-609.
9. Hensley L.E., Mulangu S., Asiedu C., Johnson J., Honko A.N., Stanley D., Fabozzi G., Nichol S.T., Ksiazek T.G., Rollin P.E., et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species. PLoS Pathog 2010, 6:e1000904.
10. Sullivan N.J., Geisbert T.W., Geisbert J.B., Xu L., Yang Z.Y., Roederer M., Koup R.A., Jahrling P.B., Nabel G.J. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003, 424:681-684.
11. Jones S.M., Feldmann H., Stroher U., Geisbert J.B., Fernando L., Grolla A., Klenk H.D., Sullivan N.J., Volchkov V.E., Fritz E.A., et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005, 11:786-790.
12. Warfield K.L., Swenson D.L., Olinger G.G., Kalina W.V., Aman M.J., Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007, 196(Suppl 2):S430-S437.
13. Geisbert T.W., Geisbert J.B., Leung A., Daddario-DiCaprio K.M., Hensley L.E., Grolla A., Feldmann H. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol 2009, 83:7296-7304.
14. Richardson J.S., Pillet S., Bello A.J., Kobinger G.P. Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J Virol 2013, 87:3668-3677.
15. Marzi A., Halfmann P., Hill-Batorski L., Feldmann F., Shupert W.L., Neumann G., Feldmann H., Kawaoka Y. Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates. Science 2015, 348:439-442.
16. Sullivan N.J., Geisbert T.W., Geisbert J.B., Shedlock D.J., Xu L., Lamoreaux L., Custers J.H., Popernack P.M., Yang Z.Y., Pau M.G., et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006, 3:e177.
17. Martin J.E., Sullivan N.J., Enama M.E., Gordon I.J., Roederer M., Koup R.A., Bailer R.T., Chakrabarti B.K., Bailey M.A., Gomez P.L., et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006, 13:1267-1277.
18. Ledgerwood J.E., Costner P., Desai N., Holman L., Enama M.E., Yamshchikov G., Mulangu S., Hu Z., Andrews C.A., Sheets R.A., et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010, 29:304-313.
19. Sullivan N.J., Hensley L., Asiedu C., Geisbert T.W., Stanley D., Johnson J., Honko A., Olinger G., Bailey M., Geisbert J.B., et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 2011, 17:1128-1131.
20. Geisbert T.W., Bailey M., Hensley L., Asiedu C., Geisbert J., Stanley D., Honko A., Johnson J., Mulangu S., Pau M.G., et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol 2011, 85:4222-4233.
21. Lichterfeld M., Yu X.G., Waring M.T., Mui S.K., Johnston M.N., Cohen D., Addo M.M., Zaunders J., Alter G., Pae E., et al. HIV-1-specific cytotoxicity is preferentially mediated by a subset of CD8(+) T cells producing both interferon-gamma and tumor necrosis factor-alpha. Blood 2004, 104:487-494.
22. Colloca S., Barnes E., Folgori A., Ammendola V., Capone S., Cirillo A., Siani L., Naddeo M., Grazioli F., Esposito M.L., et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012, 4. 115ra112.
23. Stanley D.A., Honko A.N., Asiedu C., Trefry J.C., Lau-Kilby A.W., Johnson J.C., Hensley L., Ammendola V., Abbate A., Grazioli F., et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 2014, 20:1126-1129.
24. Wong K.K., Perdue C.L., Malia J., Kenney J.L., Peng S., Gwathney J.K., Raczniak G.A. Supportive care of the first two Ebola virus disease patients at the Monrovia Medical Unit. Clin Infect Dis 2015, Advanced access published June 14th, 2015.
25. Liddell A.M., Davey R.T., Mehta A.K., Varkey J.B., Kraft C.S., Tseggay G.K., Badidi O., Faust A.C., Brown K.V., Suffredini A.F., et al. Characteristics and clinical management of a cluster of 3 patients with ebola virus disease, including the first domestically acquired cases in the United States. Ann Intern Med 2015, 163:81-90.
26. Ledgerwood J.E., DeZure A.D., Stanley D.A., Novik L., Enama M.E., Berkowitz N.M., Hu Z., Joshi G., Ploquin A., Sitar S., et al. Chimpanzee adenovirus vector Ebola vaccine-preliminary report. N Engl J Med 2014, Published online Nov 26. 10.1056/NEJMoa1410863.
27. Krause P.R., Cavaleri M., Coleman G., Gruber M.F. Approaches to demonstration of Ebola virus vaccine efficacy. Lancet Infect Dis 2015, 15:627-629.
28. Kibuuka H., Berkowitz N.M., Millard M., Enama M.E., Tindikahwa A., Sekiziyivu A.B., Costner P., Sitar S., Glover D., Hu Z., et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet 2015, 385:1545-1554.
29. Sarwar U.N., Costner P., Enama M.E., Berkowitz N., Hu Z., Hendel C.S., Sitar S., Plummer S., Mulangu S., Bailer R.T., et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis 2015, 211:549-557.
30. Rampling T., Ewer K., Bowyer G., Wright D., Imoukhuede E.B., Payne R., Hartnell F., Gibani M., Bliss C., Minhinnick A., et al. A monovalent chimpanzee adenovirus Ebola vaccine-preliminary report. N Engl J Med 2015, Published online Jan 28. 10.1056/NEJMoa1411627.
31. Bellan S.E., Pulliam J.R., Pearson C.A., Champredon D., Fox S.J., Skrip L., Galvani A.P., Gambhir M., Lopman B.A., Porco T.C., et al. Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis. Lancet Infect Dis 2015, 15:703-710.
32. Lanini S., Zumla A., Ioannidis J.P., Caro A.D., Krishna S., Gostin L., Girardi E., Pletschette M., Strada G., Baritussio A., et al. Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa?. Lancet Infect Dis 2015, 15:738-745.
33. Gonzalez S.F., Degn S.E., Pitcher L.A., Woodruff M., Heesters B.A., Carroll M.C. Trafficking of B cell antigen in lymph nodes. Annu Rev Immunol 2011, 29:215-233.
34. Quinn K.M., Zak D.E., Costa A., Yamamoto A., Kastenmuller K., Hill B.J., Lynn G.M., Darrah P.A., Lindsay R.W., Wang L., et al. Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling. J Clin Invest 2015, 125:1129-1146.